Form 4: Director Staffan Encrantz Increases Stake in Sight Sciences

Director Staffan Encrantz purchased 14,100 shares of Sight Sciences, Inc. common stock at a weighted average price of $4.879.

Summary

• Director Staffan Encrantz acquired 14,100 shares of Sight Sciences, Inc. (SGHT) on June 10, 2026.
• The shares were purchased at a weighted average price of $4.879 per share, with individual transaction prices ranging from $4.78 to $4.93.
• Following this transaction, the reporting person directly owns 1,434,283 shares.
• The reporting person also maintains indirect interests in 632,456 shares via a revocable trust and 5,086,920 shares via Allegro Investment Fund, L.P.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level insider buying often indicates confidence in the company's current market valuation.

Positives

• Insider confidence is demonstrated by a director increasing their direct equity position in the company.
• The purchase was made at market prices, signaling alignment with shareholder interests.

Negatives

• None identified in this filing.

Risks

• The reporting person disclaims beneficial ownership of shares held by the trust and investment fund, noting potential complexities in control or pecuniary interest.

Future Outlook

Not applicable as this is an insider transaction report.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the company's long-term valuation, particularly in the medical device sector where Sight Sciences operates.

Comparison to Industry Standards

• Insider purchases by directors are standard corporate governance activities and align with typical market behavior for publicly traded medical technology firms.

Related Party Transactions

• The reporting person is a trustee of the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust.
• The reporting person is the Chairman, CEO, and sole director of Allegro Investment Inc., the manager of Allegro Investment Fund, L.P.

Stakeholder Impact

• Shareholders may interpret this purchase as a vote of confidence from a long-term director.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Sight Sciences, SGHT, Insider Trading, Form 4, Staffan Encrantz, Equity Purchase